lt3001
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2019 (NCT04091945)
Timeline
Indications
Studied for
Mechanism of action
- PlasminogenACTIVATOR
PLG activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05686642 | Phase 2 | Apr 6, 2023 | Shanghai Pharmaceuticals Holding Co., Ltd |
| NCT05403866 | Phase 2 | Jun 1, 2022 | Lumosa Therapeutics Co., Ltd. |
| NCT05198323 | Phase 2 | Feb 1, 2022 | Lumosa Therapeutics Co., Ltd. |
| NCT04809818 | Phase 1 | Mar 21, 2021 | Lumosa Therapeutics Co., Ltd. |
| NCT04091945 | Phase 2 | Sep 30, 2019 | Lumosa Therapeutics Co., Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Lumosa Therapeutics Co., Ltd. | For profit | 4 | 4 | 2 | 2019 |
| Shanghai Pharmaceuticals Holding Co., Ltd | For profit | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1